Literature DB >> 6114893

Clinical significance of glucagon provocation test in the diagnosis of hypergastrinemia.

C Nakanome, A Ishimori, Y Goto, T Yamazaki, J Kameyama, I Sasaki, M Inui, Y Furukawa, K Komatsu.   

Abstract

Glucagon provocation test was performed in the patients with hypergastrinemia and hyperchlorhydria to investigate its diagnostic value. A paradoxical response of plasma gastrin level in the patients with the Zollinger-Ellison syndrome and a marked decrease of plasma gastrin level in the patients with gastric ulcer, duodenal ulcer, excluded gastric antrum, multiple endocrine adenomatosis, pernicious anemia and chronic renal failure were demonstrated by glucagon infusion. Glucagon provocation test, therefore, was considered to be of great value in the diagnosis of the Zollinger-Ellison syndrome, particularly, in the case of an excluded gastric antrum in which secretin provocation test caused the false positive result because of a marked increase of pancreatic secretion. Glucagon provocation test in combination with secretin provocation test, therefore, is at present the most preferable diagnostic procedure for detecting the Zollinger-Ellison syndrome.U

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114893     DOI: 10.1007/bf02815800

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  18 in total

1.  Diagnostic value of secretin provocation test.

Authors:  A Ishimori; K Tsuda; S Yamagata; Y Miura; T Kawamura
Journal:  Tohoku J Exp Med       Date:  1975-06       Impact factor: 1.848

2.  Natural history and experience with diagnosis and treatment of the Zollinger-Ellison syndrome.

Authors:  J C Thompson; D D Reeder; H V Villar; H R Fender
Journal:  Surg Gynecol Obstet       Date:  1975-05

3.  Antral-gastrin-cell hyperplasia in peptic-ulcer disease.

Authors:  P C Ganguli; J M Polak; A G Pearse; J B Elder; M Hegarty
Journal:  Lancet       Date:  1974-04-06       Impact factor: 79.321

4.  Hypergastrinaemia due to an excluded gastric antrum: a proposed method for differentiation from the Zollinger ellison syndrome.

Authors:  M G Korman; D F Scott; J Hansky; H Wilson
Journal:  Aust N Z J Med       Date:  1972-08

5.  Characteristics of inhibition of pancreatic secretion by glucagon.

Authors:  S J Konturek; J Tasler; W Obtulowicz
Journal:  Digestion       Date:  1974       Impact factor: 3.216

6.  The retained gastric antrum: clinical considerations.

Authors:  J A Van Heerden; P E Bernatz; R A Rovelstad
Journal:  Mayo Clin Proc       Date:  1971-01       Impact factor: 7.616

7.  Plasma and parathyroid tumor tissue gastrin and hyperparathyroidism.

Authors:  R I Wesdorp; C A Wang; H Hirsch; J E Fischer
Journal:  Am J Surg       Date:  1976-01       Impact factor: 2.565

8.  Comparative study of the value of the calcium, secretin, and meal stimulated increase in serum gastrin to the diagnosis of the Zollinger-Ellison syndrome.

Authors:  C G Lamers; J H Van Tongeren
Journal:  Gut       Date:  1977-02       Impact factor: 23.059

9.  Secretin and the Zollinger--Ellison syndrome: reliability of secretin tests and pathogenetic role of secretin.

Authors:  J G Stage; F Stadil; J F Rehfeld; J Fahrenkrug; O B Muckadell
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

10.  Observations on the postoperative tumor growth behavior of certain islet cell tumors.

Authors:  R M Zollinger; E W Martin; L C Carey; J Sparks; J P Minton
Journal:  Ann Surg       Date:  1976-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.